Driving p53 response to bax activation greatly enhances sensitivity to taxol by inducing massive apoptosis

Neoplasia

Volumn 2, Issue 3, 2000, Pages 202-207

  De Feudis, Paola ^a   Vignati, Sara ^a   Rossi, Cosmo ^b   Mincioni, Tatiana ^b   Giavazzi, Raffaella ^c   D'Incalci, Maurizio ^a   Broggini, Massimo ^a,b  

^a MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

^b Santa Maria Imbaro   (Italy)

^c MARIO NEGRI INST PHARMACOL RES   (Italy)

Author keywords

Anticancer agents; Apoptosis; p53; Transcription; Tumor xenograffs

Indexed keywords

ANTINEOPLASTIC AGENT; PACLITAXEL; PROTEIN P53;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CANCER GENETICS; MOLECULAR CLONING; MOUSE; NONHUMAN; OVARY CANCER; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN BINDING; TRANSCRIPTION REGULATION; XENOGRAFT;

EID: 0034043602     PISSN: 15228002     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.neo.7900086     Document Type: Article

References (34)

1. Ko LJ, and Prives C (1996). p53: puzzle and paradigm. Genes Dev 56, 2649-2654.
2. Levine AJ (1997). p53, the cellular gatekeeper for growth and division. Cell 88, 323-331.
3. Oren M, and Prives C (1996). p53: upstream, downstream and off stream. Review of the 8th p53 workshop (Dundee, July 5-9, 1996). Biochim Biophys Acta 1288, R13-R19.
4. Chen X, Ko LJ, Jayaraman L, and Prives C (1996). p53 levels, functional domains, and DNA damage determine the extent of the apoptotic response of tumor cells. Genes Dev 10, 2438-2451.
5. Bates S, and Vousden KH (1996). p53 in signaling checkpoint arrest or apoptosis. Curr Opin Genet Dev 6, 12-18.
6. Waldman T, Zhang Y, Dillehay L, Yu J, Kinzler K, Vogelstein B, and Williams J (1997). Cell-cycle arrest versus cell death in cancer therapy [see comments]. Nat Med 3, 1034-1036.
7. el Deiry WS, Tokino T, Velculescu VE, Levy DB, Parsons R, Trent JM, Lin D, Mercer WE, Kinzler KW, and Vogelstein B (1993). WAF1, a potential mediator of p53 tumor suppression. Cell 75, 817-825.
8. Harper JW, Adamy GR, Wei N, Keyomarsi K, and Elledge SJ (1993). The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases. Cell 75, 805-816.
9. Oltvai ZN, Milliman CL, and Korsmeyer SJ (1993). Bcl-2 heterodimerizes in vivo with a conserved homolog, Bax, that accelerates programmed cell death. Cell 74, 609-619.
10. Lill NL, Grossman SR, Ginsberg D, DeCaprio J, and Livingston DM (1997). Binding and modulation of p53 by p300/CBP coactivators. Nature 387, 823-827.
11. Vikhanskaya F, Vignati S, Beccaglia P, Ottoboni C, Russo P, D'Incalci M, and Broggini M (1998). Inactivation of p53 in a human ovarian cancer cell line increases the sensitivity to paclitaxel by inducing G2/M arrest and apoptosis. Exp Cell Res 241, 96-101.
12. Wahl AF, Donaldson KL, Fairchild C, Lee FY, Foster SA, Demers GW, and Galloway DA (1996). Loss of normal p53 function confers sensitization to Taxol by increasing G2/M arrest and apoptosis. Nat Med 2, 72-79.
13. Fan S, Smith ML, Rivet DJ, Duba D, Zhan Q, Kohn KW, Fornace AJJ, and O'Connor PM (1995). Disruption of p53 function sensitizes breast cancer MCF-7 cells to cisplatin and pentoxifylline. Cancer Res 55, 1649-1654.
14. Waldman T, Kinzler KW, and Vogelstein B (1995). p21 is necessary for the p53-mediated G1 arrest in human cancer cells. Cancer Res 55, 5187-5190.
15. Sakakura C, Sweeney EA, Shirahama T, Igarashi Y, Hakomori S, Nakatani H, Tsujimoto H, Imanishi T, Ohgaki M, Ohyama T, et al. (1996). Overexpression of baxsensitizes human breast cancer MCF-7 cells to radiation-induced apoptosis. Int J Cancer 67, 101-105.
16. Yin C, Knudson CM, Korsmeyer SJ, and Van Dyke T (1997). Bax suppresses tumorigenesis and stimulates apoptosis in vivo. Nature 385, 637-640.
17. Strobel T, Swanson L, Korsmeyer S, and Cannistra SA (1996). BAX enhances paclitaxel-induced apoptosis through a p53-independent pathway. Proc Natl Acad Sci USA 93, 14094-14099.
18. Rossè T, Olivier R, Monney L, Rager M, Conus S, Fellay I, Jansen B, and Borner C (1998). Bcl-2 prolongs cell survival after Bax-induced release of cytochrome c. Nature 391, 496-499.
19. Debernardis D, Sire EG, De Feudis P, Vikhanskaya F, Valenti M, Russo P, Parodi S, D'Incalci M, and Broggini M (1997). p53 status does not affect sensitivity of human ovarian cancer cell lines to paclitaxel. Cancer Res 57, 870-874.
20. De Feudis P, Debernardis D, Beccaglia P, Valenti M, Graniela Siré EA, Arzani D, Stanzione S, Parodi S, D'Incalci M, Russo P, et al. (1997). DDP-induced cytotoxicity is not influenced by p53 in nine human ovarian cancer cell lines with different p53 status. Br J Cancer 76, 474-479.
21. Sambrook J, Fritsch EF, and Maniatis T (1989). Molecular Cloning: A Laboratory Manual. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y.
22. Boven E, Winograd B, Berger DP, Dumont MP, Braakhuis BJ, Fodstad O, Langdon S, and Fiebig HH (1992). Phase II preclinical drug screening in human tumor xenografts: a first European multicenter collaborative study. Cancer Res 52, 5940-5947.
23. Miyashita T, and Reed JC (1995). Tumor suppressor p53 is a direct transcriptional activator of the human tax gene. Cell 80, 293-299.
24. Krajewski S, Blomqvist C, Franssila K, Krajewska M, Wasenius V, Niskanen E, Nordling S, and Reed JC (1995). Reduced expression of proapoptotic gene bax is associated with poor response rates to combination chemotherapy and shorter survival in women with metastatic breast adenocarcinoma. Cancer Res 55, 4471-4478.
25. Simonian PL, Grillot DA, Andrews DW, Leber B, and Nunez G (1996). Bax homodimerization is not required for Bax to accelerate chemotherapy-induced cell death. J Biol Chem 271, 32073-32077.
26. Kobayashi T, Ruan S, Clodi K, Kliche OK, Shiku H, Andreef M, and Zhang W (1998). Overexpression of bax gene sensitizes K562 erythroleukemia cells to apoptosis induced by selective chemotherapeutic agents. Oncogene 16, 1587-1591.
27. Rowinsky EK, and Donehower RC (1995). Paclitaxel (taxol). N Engl J Med 332, 1004-1014.
28. Yang J, Liu X, Bhalla K, Kim N, Ibrado AM, Cai J, Peng T, Jones DP, and Wang X (1997). Prevention of apoptosis by bcl-2: release of cytochrome c from mitochondria blocked. Science 275, 1129-1132.
29. Nicoletti Ml, Lucchini V, Masazza G, Abbott BJ, D'Incalci M, and Giavazzi R (1993). Antitumor activity of taxol (NSC-125973) in human ovarian carcinomas growing in the peritoneal cavity of nude mice. Ann Oncol 4, 151-155.
30. Adler V, Pincus MR, Minamoto T, Fuchs SY, Bluth MJ, Brandt Rauf PW, Friedman FK, Robinson RC, Chen JM, Wang XW, et al. (1997). Conformation-dependent phosphorylation of p53. Proc Natl Acad Sci USA 94, 1686-1691.
31. Reinke V, and Lozano G (1997). Differential activation of p53 targets in cells treated with ultraviolet radiation that undergo both apoptosis and growth arrest. Radiat Res 148, 115-122.
32. Lohrum M, and Scheidtmann KH (1996). Differential effects of phosphorylation of rat p53 on transactivation of promoters derived from different p53 responsive genes. Oncogene 13, 2527-2539.
33. Siciliano JD, Canman CE, Taya Y, Sakaguchi K, Appella E, and Kastan MB (1997). DNA damage induces phosphorylation of the amino terminus of p53. Genes Dev 11, 3471-3481.
34. Shieh S-Y, Ikeda M, Taya Y, and Prives C (1997). DNA damage-induced phosphorylation of p53 alleviates inhibition by MDM2. Cell 91, 325-334.